Yasuto Naoi

E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114

Hiroshi Ishiguro, Yasuo Miyoshi, Hiroyuki Yasojima, Junichiro Watanabe et autres

BACKGROUND: There is an ongoing need for first-line (1L) chemotherapies for metastatic HER2-negative breast cancer. This study evaluated the efficacy and safety profile of the dose-expansion part 6 of Study 114 in patients receiving E7389-LF as a 1L chemotherapy for metastatic/advanced HER2-negative …

jp (code pays fourni par la source)

Focal adhesion kinase inhibitor defactinib enhances olaparib‑induced suppression of BRCA‑proficient breast cancer cell proliferation

Hisako Ono, KEIKO TANIGUCHI, Shusuke Yasuda, Mamiko Sukeno et autres

Poly ADP-ribose polymerase (PARP) inhibitors exhibit high activity for carcinomas with homologous recombination (HR) deficiency, such as BRCA1/2 mutations.PARP inhibitors are primarily administered to patients with breast cancer with BRCA germline mutations; therefore, the use of these inhibitors for breast cancer has …

jp (code pays fourni par la source)

Weakly supervised attention-based learning supports breast cancer detection on deep ultraviolet-excitation fluorescence images

Ryuta Nakao, Tomoya Matsui, Masatoshi Abe, Mizuki Honda et autres

Abstract Microscopy with ultraviolet surface excitation (MUSE) enables rapid fluorescence imaging of fresh tissue surfaces without conventional sectioning, but its appearance differs from that of haematoxylin and eosin-stained slides. Pixel- or patch-level annotation for deep learning is laborious, particularly for emerging imaging …

jp (code pays fourni par la source)

Clinical implications of discordance in HER2 reassessment from HercepTest to 4B5 in metastatic breast cancer

Yuhei Yamaguchi, Mai Hoshino, Tatsunori Shimoi, H Tamura et autres

PURPOSE: and 4B5 and identify associated clinicopathological factors. METHODS: We retrospectively analyzed patients who underwent prior HER2 testing with HercepTest and subsequent reassessment with 4B5 between May 2023 and November 2024 at our institution. The primary endpoint was reassessment discordance, and secondary …

jp, us (code pays fourni par la source)

Comparative evaluation of treatment recommendations generated by generative AI and breast cancer specialists for advanced and recurrent breast cancer: a multidimensional assessment of evidence interpretation and clinical decision support

Maiko Nishida, Rie Tou, Hiroki Kato, Nagisa Hirotani et autres

jp (code pays fourni par la source)

Semantic Segmentation for Pixel-Wise Visualization of Breast Cancer in Deep Ultraviolet-Excited Fluorescence Images

Tomoya Matsui, Ryuta Nakao, Shunsuke Tomimoto, Junya Sato et autres

Microscopy with ultraviolet surface excitation (MUSE) enables rapid fluorescence imaging of tissue surfaces, but MUSE images differ markedly from conventional hematoxylin and eosin images, making cancer delineation challenging for routine pathological practice. We investigated the feasibility of deep learning-based semantic segmentation, which …

jp, ca (code pays fourni par la source)

Identification of ANT2 as a Druggable Target for Endocrine-Resistant ERα-Positive Breast Cancer

Erika Iguchi, Motoki Watanabe, Kaito Kobayashi, Shogen Boku et autres

Endocrine therapy is the mainstay for estrogen receptor (ER) α-positive breast cancer (BC), yet many patients display acquired resistance. We then screened natural compounds using human ERα-positive BC cells and identified perillyl alcohol (POH), a monoterpene from perilla, that reduces ERα protein …

jp (code pays fourni par la source)

Real-World Landscape of Genomic Medicine in Breast Cancer Revealed by the C-CAT Database: Reappraisal of Drug Accessibility and Clinical Utility in 6,307 Patients

M. Morita, Sae Kitano, Ryo Tsunashima, T. Yoshinami et autres

jp, pl (code pays fourni par la source)

Integration of gene expression profiling and mutation analysis via RNA sequencing: transitioning the 95-gene classifier to a next-generation platform in early-stage HR+/HER2- breast cancer

Chikage Kato, Yoshiaki Sota, Sae Kitano, A. Watanabe et autres

jp (code pays fourni par la source)

A Radiogenomic Model using MRI and Gene Signature to Predict Complete Response in Breast Cancer

Yukiko Tokuda, Yuki Suzuki, Soya Oda, Yoshiaki Sota et autres

jp, ca (code pays fourni par la source)

Copy Number–Based Chromosomal Instability Ex-Score Predicts Breast Cancer Malignancy

Chise Matsui, Seiichi Imanishi, Chikage Kato, Akira Watanabe et autres

jp (code pays fourni par la source)

Abstract PS1-05-27: A Multicenter Randomized Controlled Trial to Verify the Preventive Effect of Denosumab against Cancer Treatment-Induced Bone Loss (CTIBL) in Breast Cancer Patients Receiving Postoperative Endocrine Therapy with Normal Bone Density

M. Morita, A. Watanabe, K. Sakaguchi, I. Takashi et autres

Abstract Background: Aromatase inhibitors (AIs) are widely used as postoperative endocrine therapy in patients with postmenopausal hormone receptor-positive breast cancer. The main side effect of AIs is bone loss, which is called cancer treatment-induced bone loss (CTIBL), and the use of bone …

jp (code pays fourni par la source)